Loading...
•
Mar 31, 2022
Sage Q1 2022 Earnings Report
Reported business highlights and financial results.
Key Takeaways
Sage Therapeutics reported its Q1 2022 financial results, highlighted by the initiation of a rolling NDA submission for zuranolone in MDD and progress across its pipeline. The company's cash, cash equivalents, and marketable securities totaled $1.6 billion. Net revenue from ZULRESSO sales was $1.6 million, and the net loss was $122.1 million.
Initiated rolling NDA submission for zuranolone in MDD, with full submission expected in the second half of 2022.
Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD is on track for mid-2022.
Executing four Phase 2 studies across neuropsychiatry and neurology franchises.
Company leadership strengthened with the appointment of Mark Pollack, M.D., as Senior Vice President, Medical Affairs.
Forward Guidance
Sage anticipates having approximately $1.3 billion in cash, cash equivalents, and marketable securities at the end of 2022. The company does not anticipate receiving any milestone payments from collaborations in 2022 and believes its cash will support operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...